For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stua
For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial.Stuart Connollyfrom McMaster University presented the findings.
Related Episodes
Audio Journal of Oncology Volume 16 Number 8
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu